TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05102552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPN-817, Treatment B
Description: SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPN-817, Treatment C
Description: SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIS-001, Treatment A
Description: BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIS-001, Treatment A
Description: BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
Study: NCT04942782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: Patients will received strengthening exercises for the abdominal, back, and hip muscles. The patients performed an average of three series of ten repetitions of each exercise. Increases in the number of exercises performed in each session (or load progression) occurred according to individual tolerance
Study: NCT06469606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI tool
Description: Both the arms will undergo the use of AI tool developed in the group. The tool will be trained to detect outcomes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI tool
Description: Both the arms will undergo the use of AI tool developed in the group. The tool will be trained to detect outcomes.
Study: NCT06469528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Low dose daily colchicine
Study: NCT05695924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioBridge® Collagen Matrix
Description: BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascularized Lymph Node Transfer (VLNT)
Description: Micro-surgical procedure for vascularized lymph node transfer (VLNT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vascularized Lymph Node Transfer (VLNT)
Description: Micro-surgical procedure for vascularized lymph node transfer (VLNT)
Study: NCT06024018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high intensity electromagnetic technology device, diet restriction, and walking
Description: thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months. Also they will undergo high intensity electromagnetic technique (40 minutes for every session) on abdomen of males which will be 3 sessions per week for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet restriction and walking
Description: thirty obese males (30 males) will undergo dietary caloric restriction and will be instructed to walk 10,000 continuous steps every day using the pedometer application for 3 months.
Study: NCT05258929

Intervention type: OTHER
Intervention: Data collection (Prior and planned treatments, allograft)
Description: MHLC questionnaire (Multidimensional Health Locus of Control) when a novel therapeutic strategy is set up
Study: NCT05739409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LILRB4 STAR-T cells injection
Description: The study population was relapsed/refractory acute myeloid leukemia and chronic myelomonocytic leukemia.Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg
Study: NCT06389110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alleance®
Description: Atropine sulfate 0.01%, ophthalmic solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ophthalmic solution.
Study: NCT06395532

Intervention type: OTHER
Intervention: Observetional
Description: After admission to the ICU, patients will be continuously monitored with ICU standard monitoring in addition to IPI using (Capnostream™ Medtronic). IPI will be recorded after transfer to the ICU, as well as at 2, 6, 12, 18 and 24 hours.

Intervention type: OTHER
Intervention: Observetional
Description: After admission to the ICU, patients will be continuously monitored with ICU standard monitoring in addition to IPI using (Capnostream™ Medtronic). IPI will be recorded after transfer to the ICU, as well as at 2, 6, 12, 18 and 24 hours.
Study: NCT05150522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T cells
Description: BCMA CAR-T cells infusion
Study: NCT06233097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole magnesium dihydrate-Test product
Description: Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole magnesium dihydrate-Reference product
Description: Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
Study: NCT02436954

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CO2 insufflation at intra-abdominal pressure 8 mmHg
Description: insufflation of CO2 gas into peritoneum for maintaining the pressure of 8 mmHg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 insufflation at intra-abdominal pressure 12 mmHg
Description: insufflation of CO2 gas into peritoneum for maintaining the pressure of 12 mmHg
Study: NCT05784298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity rTMS
Description: 40 hz, 150 gauss, 1 session that lasts 45 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: low-intensity rTMS
Description: 40 hz, 150 gauss, 1 session that lasts 45 minutes.
Study: NCT05278832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31905
Description: QLS31905 injection
Study: NCT06525701

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Execise Group
Description: SCORE workout: eight exercises done sequentially: bicycles, balancing dog, windshield wipers, three-point plank, kayaker, super push-ups, bridge, and side plank. These workouts are modified from the core regimen recommended by Steve House and Scott Johnston in their book Training for the New Alpinism: A Manual for the Climber as Athlete (House 2014). Each exercise is done until fatigue: when the individual is no longer able to complete the exercise with good form. The participant then rests for approximately thirty to sixty seconds before beginning the next exercise. Passive stretching can be performed during the rest periods. The workout is complete at twenty minutes. Those individuals who complete all eight exercises in less than twenty minutes begin again with the first exercise (bicycles) and continue until reaching twenty minutes. The workout is thus adaptive-seamlessly increasing in repetitions as an individual's strength and endurance increase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Execise Group
Description: SCORE workout: eight exercises done sequentially: bicycles, balancing dog, windshield wipers, three-point plank, kayaker, super push-ups, bridge, and side plank. These workouts are modified from the core regimen recommended by Steve House and Scott Johnston in their book Training for the New Alpinism: A Manual for the Climber as Athlete (House 2014). Each exercise is done until fatigue: when the individual is no longer able to complete the exercise with good form. The participant then rests for approximately thirty to sixty seconds before beginning the next exercise. Passive stretching can be performed during the rest periods. The workout is complete at twenty minutes. Those individuals who complete all eight exercises in less than twenty minutes begin again with the first exercise (bicycles) and continue until reaching twenty minutes. The workout is thus adaptive-seamlessly increasing in repetitions as an individual's strength and endurance increase.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No additional exercises or tasks are requested of control participants. Control group participants will perform or not perform exercise as they otherwise would outside of the study.
Study: NCT05575232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application Group (GA)
Description: The main focus of the application is to assist in the treatment of patients with SAH. The application will address the components of adherence to medication use, blood pressure monitoring and promotion/monitoring of physical activity. In addition, health education tips will be provided, including guidelines for reducing sodium consumption, adopting an adequate and healthy diet, controlling body weight, moderate alcohol consumption and stress management, in accordance with the recommendations of the main guidelines related to the theme¹ ³. The intervention will last eight weeks.
Study: NCT06525701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: No additional exercises or tasks are requested of control participants. Control group participants will perform or not perform exercise as they otherwise would outside of the study.
Study: NCT05695066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative fasting instruction
Description: Patients parents instructed to stop enteral feeding at a specified time before predicted anesthesia induction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative fasting instruction
Description: Patients parents instructed to stop enteral feeding at a specified time before predicted anesthesia induction
Study: NCT04767438

Intervention type: OTHER
Intervention: Pregnant women
Description: All pregnant women that present to the 12-week scan in the Obstetrics Unit
Study: NCT05153525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent boluses of Cisatracurium
Description: Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of Cisatracurium for 24 hours
Description: Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
Study: NCT04849715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parsaclisib
Description: parsaclisib will be administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: rituximab is administered IV on Day 1 of each 28-day cycle for 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rituximab
Description: rituximab is administered IV on Day 1 of each 28-day cycle for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bendamustine
Description: bendamustine is administered IV on Day 1 and 2 of each 28-day cycle for 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bendamustine
Description: bendamustine is administered IV on Day 1 and 2 of each 28-day cycle for 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo will be administered orally once daily
Study: NCT04929080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: 200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: 200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: 200mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
Description: 600mg:JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001 and JS004
Description: Part B: 100mg JS004 + 240mg JS001 or 200mg JS004+ 240mg JS001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001 and JS004
Description: Part B: 100mg JS004 + 240mg JS001 or 200mg JS004+ 240mg JS001
Study: NCT05801614

Intervention type: OTHER
Group type: OTHER
Intervention: Low carb diet
Description: Low calori diet

Intervention type: OTHER
Group type: OTHER
Intervention: Low carb diet
Description: Low calori diet
Study: NCT06328309

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation treatment
Description: This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
Study: NCT05768360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: The subjects will receive single dose of oral film-coated tablet of Savolitinib A dose on Day 1 of Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: The subjects will receive single dose of oral uncoated tablet of Digoxin Dose B on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: The subjects will receive single dose of oral film-coated tablet of Metformin Hydrochloride Dose D on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: The subjects will receive single dose of oral film-coated tablet of Rosuvastatin Dose E on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: The subjects will receive single dose of oral solution of Furosemide Dose C on Day 1 of Period 1 and Period 2 within 25 minutes \[+ 5 minutes\] from the start of meal.
Study: NCT05895591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-aging cosmetic care product
Description: * frequency of application: Once a day (in the morning)~* modalities of application: Apply the cream on face (according to normal conditions of use) and on treated forearm, massage until complete penetration~* area: The whole face, neck, neckline and one randomized forearm (external photo-exposed area) the other forearm is untreated~* duration of investigational product application: 56 days (a window of + 72 hours is allowed)~* quantity: 2 pressures of product for the whole face, neck and neckline and 1 pressure of product for the treated forearm
Study: NCT04536207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy (apparatus)
Description: Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists
Study: NCT04990713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)
Description: Patients will receive local anesthetic via serratus plane block as opposed to saline placebo

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)
Description: Patients will receive saline placebo via serratus plane block
Study: NCT06004791

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Herombopag + CsA
Description: Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO combined with Herombopag + CsA
Description: rhTPO (15000U, subcutaneous injection, once a day for 7 days, once a month for 3 months)，Herombopag（10mg/d）+CsA(3-5 mg/kg/d, adjust the grain concentration 100-200ng/ml)
Study: NCT05756036

Intervention type: OTHER
Intervention: None Observational study
Description: Non interventional study
Study: NCT05669651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from healthy people's feces into patients' intestines to rebuild new intestinal flora and achieve the treatment of intestinal and parenteral diseases. In this study, 100 patients with recurrent hepatic encephalopathy were randomly divided into 1:1 groups to receive FMT with different amounts of bacteria, observe the therapeutic effect and adverse reactions of hepatic encephalopathy, and evaluate the effectiveness and safety of the two groups of patients. At the same time, the blood and stool samples of patients with recurrent hepatic encephalopathy before and after FMT were collected clinically, the composition of bile acid and other metabolites in stool and serum samples was analyzed, and the effective core flora was identified to clarify the mechanism of intestinal bacteria transplantation for the treatment of recurrent hepatic encephalopathy.
Study: NCT05810103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: DP303c injection, 3.0 mg/kg, every 3 weeks.
Study: NCT05621174

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamfetamine
Description: Magisterial Dexamfetamine

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamfetamine
Description: Tentin
Study: NCT05557305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videogame therapy
Description: There will be 5 video game-type applications for virtual therapy, each with a specific therapeutic objective, which will be administered by trained personnel, depending on the characteristics of each patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Occupational therapy with different play materials
Study: NCT05655013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: zoledronate 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: zoledronate 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: zoledronate 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isotonic saline 100 mL
Study: NCT06457841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Discrimination
Description: Simulated racial discrimination that is received directly from a perpetrator, commonly experienced in everyday lives by African American individuals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vicarious Discrimination
Description: Hearing or observing racial discrimination experienced by another person of the same racial background
Study: NCT05047848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: chidamide 30mg orally，Biw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
Study: NCT05330091

Intervention type: DIETARY_SUPPLEMENT
Intervention: Once Daily Women's Probiotic
Description: Active product

Intervention type: OTHER
Intervention: Placebo
Description: Placebo product
Study: NCT05490927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microaggression Recall and Relapse Analogue Task
Description: Participants will engage in a microaggression recall task followed by the McKee Experimental Relapse Analogue Task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microaggression Recall and Relapse Analogue Task
Description: Participants will engage in a microaggression recall task followed by the McKee Experimental Relapse Analogue Task